Enzo Biochem’s Life Sciences Unit Reaches $35 Million Patent Infringement Settlement in Delaware With Life Technologies Corporation

NEW YORK–(BUSINESS WIRE)–Enzo Biochem, Inc. (NYSE:ENZ) today announced that its subsidiary, Enzo
Life Sciences, Inc., has reached and finalized a settlement with Life
Technologies Corporation, a subsidiary of Thermo Fisher Scientific Inc.
(NYSE:TMO), involving payment of $35 million to Enzo in an action
brought in Delaware Federal District Court by Enzo alleging infringement
of its U.S. Patents Nos. 6,992,180 entitled Oligo- or Polynucleotides
Comprising Phosphate Moiety Labeled Nucleotides and 7,064,197 entitled
System, Array and Non-Porous Solid Support Comprising Fixed or
Immobilized Nucleic Acids.
Today’s settlement resolving the dispute between Enzo Life Sciences and
Life Technologies impacts only one of 11 cases originally brought by
Enzo in the United States District Court for the District of Delaware
alleging patent infringements against various companies, four of which
are now resolved and seven of which remain pending. This settlement does
not affect Enzo Life Science’s action brought in Federal District Court
in New Haven, CT against Life Technologies’ predecessors Applera Corp.
and Tropix, Inc., which remains on appeal in the U.S. Court of Appeals
for the Federal Circuit.
About
Enzo Biochem
Enzo Biochem is a pioneer in molecular diagnostics, leading the
convergence of clinical laboratories, life sciences and intellectual
property through the development of unique diagnostic platform
technologies that provide numerous advantages over previous standards. A
global company, Enzo Biochem utilizes cross-functional teams to develop
and deploy products systems and services that meet the ever-changing and
rapidly growing needs of health care both today and into the future.
Underpinning Enzo Biochem’s products and technologies is a broad and
deep intellectual property portfolio, with patent coverage across a
number of key enabling technologies.
Except for historical information, the matters discussed in this news
release may be considered “forward-looking” statements within the
meaning of Section 27A of the Securities Act of 1933, as amended and
Section 21E of the Securities Exchange Act of 1934, as amended. Such
statements include declarations regarding the intent, belief or current
expectations of the Company and its management, including those related
to cash flow, gross margins, revenues, and expenses are dependent on a
number of factors outside of the control of the company including, inter
alia, the markets for the Company’s products and services, costs of
goods and services, other expenses, government regulations, litigations,
and general business conditions. See Risk Factors in the Company’s Form
10-K for the fiscal year ended July 31, 2015. Investors are cautioned
that any such forward-looking statements are not guarantees of future
performance and involve a number of risks and uncertainties that could
materially affect actual results. The Company disclaims any obligations
to update any forward-looking statement as a result of developments
occurring after the date of this press release.